Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00667797 · ClinicalTrials.gov registry record · Phase 4
Costs & Outcomes of Hospitalization/Treatment With Levalbuterol & Albuterol in Asthma or Chronic Obstructive Pulmonary Disease (COPD) Subjects
A Phase 4 study, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- Phase 4
- Development phase
- 486
- Enrollment target
NCT00667797: Completed Phase 4 study, sponsored by Sumitomo Pharma America.
NCT00667797 is a Phase 4 study that has completed, run by Sumitomo Pharma America. The registered enrollment target is 486 participants, roughly in line with the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00667797, a Phase 4 study, has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 486 participants
- Enrollment target
Study Summary
An analysis of the costs and outcomes associated with hospitalization and treatment of Levalbuterol versus Racemic Albuterol in subjects with Asthma and COPD.
Interventions
- DRUG levalbuterol HCl
- DRUG albuterol Sulfate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 486 participants |
| Start Date | 2003-03 |
| Est. Completion | 2005-05 |
| Phase | Phase 4 |
What the finished NCT00667797 record still lists
NCT00667797 is an interventional study that assigns participants to a tested intervention. The registered 486 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target.
The record links to 0 conditions, and to 2 interventions - of which levalbuterol HCl is the first listed.
NCT00667797 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00667797 about?
NCT00667797 is a clinical study titled "Costs & Outcomes of Hospitalization/Treatment With Levalbuterol & Albuterol in Asthma or Chronic Obstructive Pulmonary Disease (COPD) Subjects". An analysis of the costs and outcomes associated with hospitalization and treatment of Levalbuterol versus Racemic Albuterol in subjects with Asthma and COPD.
What is the current status of trial NCT00667797?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 486 participants. The study started on 2003-03. Estimated completion is 2005-05.
What interventions are being tested in trial NCT00667797?
The interventions under investigation include: levalbuterol HCl (DRUG), albuterol Sulfate (DRUG).
Who is sponsoring clinical trial NCT00667797?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00667797's enrollment target sits among peer trials
486 180th of 2000 higher than 1,821 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06420531 · 486 participants · NA
Milk And Growth In Children (MAGIC) Born Very Preterm: A Randomized Trial
- NCT07097142 · 486 participants · Phase 3
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
- NCT06948435 · 487 participants · Phase 3
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
- NCT06952530 · 487 participants · Phase 3
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia